eq Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Jefferies, SVB Leerink and Guggenheim Securities are acting as joint book-running managers for the offering.